EuroBiotech: More Articles of Note

Acousia Therapeutics reeled in $10 million in series B funding. (NS Newsflash/CC BY 2.0)

> PhoreMost raised an £11 million ($15 million) series A round to expand its drug discovery activities. The Cambridge, U.K.-based startup is built upon a phenotypic screening platform. Statement

> CellCentric pulled in $26 million to fund clinical development of an inhibitor of p300 and CBP. The inhibition of the proteins is expected to cut expression of drivers of late-stage prostate cancer. Release 

> Polyphor raised CHF 165 million ($164 million) through an IPO in Switzerland. The IPO hit the upper end of the range and sold out its upsized overallotment. Polyphor is working on a phase 3 antibiotic and clinical-stage cancer asset. Statement 


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> Medicxi Ventures and RA Capital drove Xenikos to a $30 million series B. The Dutch biotech will spend the money on phase 3 trials of a treatment for graft versus host disease. Release 

> Acousia Therapeutics reeled in $10 million in series B funding. The money will support work on a pipeline of preclinical hearing loss prospects. Statement 

> Motif Bio filed to raise £10 million ($14 million). The money will support filings for approval of antibiotic iclaprim. Release

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.